A very recent study demonstrated that the combination of MEK and HDAC inhibitors considerably decreased tumor growth in both subcutaneous and liver metastasis xenograft models of UM, which encourages clinical co-targeting of MEK and HDAC in advanced UM [86]. Here, MAP2K7 is linked to neoplasm.